Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Loyola University receives funds to renovate bone marrow transplant unit

Loyola University Medical Center has received a $2 million matching grant from The Coleman Foundation to renovate the hospital's nationally known bone marrow transplant unit. Intended to encourage private donations for the project, the grant will match gifts up to $2 million on a dollar for dollar basis, through August 2010.

15 Sep 2009

Malnutrition, poor sanitary conditions and HIV leads to defective immune system

The most common causes worldwide include malnutrition, poor sanitary conditions and human immune deficiency virus (HIV) infection. Other causes of temporary or permanent damage to the immune system include old age, medications (e.g. cortisone, cytostatic drugs), radiotherapy, stress after surgery and malignant tumors of the bone marrow and the lymph nodes.

14 Sep 2009

Genoptix to present an overview of its specialized diagnostic laboratory services business

Genoptix, Inc., a specialized laboratory services provider, today announced the Company's participation at the following upcoming investor conferences.

14 Sep 2009

Master gene could lead to new ways of cancer treatments

The master gene that causes blood stem cells to turn into disease-fighting 'Natural Killer' (NK) immune cells has been identified by scientists, in a study published in Nature Immunology today. The discovery could one day help scientists boost the body's production of these frontline tumour-killing cells, creating new ways to treat cancer.

14 Sep 2009

Pluristem begins enrollment following FDA approval for clinical trials of its PLX-PAD stem cell product

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

11 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Ascent Therapeutics demonstrates Pepducin efficacy

Ascent Therapeutics announced today that the Company has demonstrated efficacy in preclinical models in two Pepducin projects. One of the projects targets CXCR4, a key regulator of stem cell and inflammatory cell homeostasis. A second project has yielded the first potent Pepducin agonists for an undisclosed cardiovascular target.

11 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."

10 Sep 2009

ThermoGenesis releases results for fourth quarter and fiscal year 2009

ThermoGenesis Corp. , a leading supplier of innovative products for processing and storing adult stem cells, today reported results for the fourth quarter and all of fiscal 2009.

10 Sep 2009

Chemgenex completes NDA submission for its omacetaxine mepesuccinate to the FDA

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

9 Sep 2009

INSPIRE Phase I/IIa study data to be presented at ICAAC

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its INSPIRE Phase I/IIa study of HIV-infected patients with low CD4 T cell counts treated with a three injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), will be presented during an oral late breaker session at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held September 12-15, 2009, in San Francisco, CA.

9 Sep 2009

Preliminary results of Phase III Gvhd trials announced by Osiris Therapeutics

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). GvHD, the most common complication of bone marrow transplantation, is a life-threatening disease for which there is currently no approved treatment. Prochymal showed significant improvements in response rates in difficult-to-treat liver and gastrointestinal GvHD, however neither trial reached its primary endpoint.

8 Sep 2009

Protalix receives orphan drug designation for prGCD

Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that the FDA’s Office of Orphan Products Development has granted orphan drug designation to prGCD, the Company’s proprietary plant cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.

8 Sep 2009

$geneX combined with Mesenchymal stem cells for treating fracture$

geneX combined with Mesenchymal stem cells for treating fracture

Professor James B. Richardson of the Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK has been carrying out pioneering work combining geneX with selected and culture expanded Mesenchymal stem cells to treat fracture non-unions.

7 Sep 2009

Five Clinical Research Units established

With the establishment of five new Clinical Research Units the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) hopes to give a further boost to clinical research in Germany and drive progress in the scientific investigation and possibilities for the treatment of disease.

7 Sep 2009

New approach for understanding how drug resistance occurs in leukemia

UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.

5 Sep 2009

IND for Cytopia's CYT387 clears the FDA review

Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.

4 Sep 2009

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

A key compound resupplies bone marrow with fast-acting stem cells that can more quickly rekindle blood cell production, according to a study published online today in the journal Blood. While the study was in mice, in the study authors say it has the potential to increase survival among patients with life-threatening blood cell shortages.

3 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009